文献速递乳腺癌

依西美坦替代给药方案在0至II期雌激素受体阳性绝经后乳腺癌女性中的疗效:一项随机临床试验

Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor-Positive Breast Cancer: A Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2023-01-01

这项多中心、术前、双盲2b期随机临床试验纳入180例绝经后雌激素受体阳性乳腺癌患者,比较依西美坦25 mg每日一次、每周三次或每周一次术前给药4至6周。意向治疗人群(n=171)中,三组血清雌二醇最小二乘均值百分比变化分别为-89%、-85%和-60%;每日一次与每周三次组间差异为-3.6%(非劣效性P=.37),而在依从参与者(n=153)中该差异为2.0%(97.5%置信下限-5.6%;非劣效性P=.02)。结论认为在依从患者中每周三次给药对降低血清雌二醇非劣效于每日一次。

要点

  • 依从患者中依西美坦25 mg每周三次降低血清雌二醇非劣效于每日一次。
  • 意向治疗人群每日一次与每周三次组雌二醇变化差异-3.6%,非劣效性P=.37。
  • 每周三次组性激素结合球蛋白和高密度脂蛋白胆固醇谱优于每日一次组。

核心结论

  • 在依从患者中,依西美坦25 mg每周三次降低血清雌二醇非劣效于每日一次剂量。
  • 作者建议这一新方案应在预防研究和辅助治疗中不能耐受每日剂量的女性中进一步研究。

研究设计与样本

  • 多中心、术前、双盲2b期随机临床试验,评估依西美坦两种替代给药方案。
  • 筛查2017年2月1日至2019年8月31日期间适合乳腺手术的绝经后雌激素受体阳性乳腺癌女性。
  • 共180例女性随机分入每日一次、每周三次或每周一次三组,术前给药4至6周。
  • 主要终点为血清雌二醇浓度变化,非劣效性界值为-6%。

主要发现

  • 意向治疗人群(n=171)中,血清雌二醇最小二乘均值百分比变化每日一次组(n=55)为-89%,每周三次组(n=56)为-85%,每周一次组(n=60)为-60%。
  • 每日一次与每周三次组间雌二醇百分比变化差异为-3.6%(非劣效性P=.37)。
  • 依从参与者(n=153)中,每日一次与每周三次组间差异为2.0%(97.5%置信下限-5.6%;非劣效性P=.02)。
  • Ki-67中位绝对百分比变化每日一次组为-7.5%,每周三次组为-5.0%,每周一次组为-4.0%(每日一次vs每周三次P=.31;每日一次vs每周一次P=.06)。
  • 孕激素受体中位绝对百分比变化每日一次组为-17.0%,每周三次组为-9.0%,每周一次组为-7.0%。

关键数值与推荐

  • 非劣效性界值为-6%。
  • 依从参与者中每日一次与每周三次组雌二醇变化差异2.0%(97.5%置信下限-5.6%;非劣效性P=.02)。

临床怎么用

  • 作者认为每周三次依西美坦25 mg方案应在预防研究和辅助治疗中不能耐受每日剂量的女性中进一步研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Successful therapeutic cancer prevention requires definition of the minimal effective dose. Aromatase inhibitors decrease breast cancer incidence in high-risk women, but use in prevention and compliance in adjuvant settings are hampered by adverse events. OBJECTIVE: To compare the noninferiority percentage change of estradiol in postmenopausal women with estrogen receptor-positive breast cancer given exemestane, 25 mg, 3 times weekly or once weekly vs a standard daily dose with a noninferiority margin of -6%. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, presurgical, double-blind phase 2b randomized clinical trial evaluated 2 alternative dosing schedules of exemestane. Postmenopausal women with estrogen receptor-positive breast cancer who were candidates for breast surgery were screened from February 1, 2017, to August 31, 2019. Blood samples were collected at baseline and final visit; tissue biomarker changes were assessed from diagnostic biopsy and surgical specimen. Biomarkers were measured in different laboratories between April 2020 and December 2021. INTERVENTIONS: Exemestane, 25 mg, once daily, 3 times weekly, or once weekly for 4 to 6 weeks before surgery. MAIN OUTCOMES AND MEASURES: Serum estradiol concentrations were measured by solid-phase extraction followed by liquid chromatography-tandem mass spectrometry detection. Toxic effects were evaluated using the National Cancer Institute terminology criteria, and Ki-67 was assessed by immunohistochemistry. RESULTS: A total of 180 women were randomized into 1 of the 3 arms; median (IQR) age was 66 (60-71) years, 63 (60-69) years, and 65 (61-70) years in the once-daily, 3-times-weekly, and once-weekly arms, respectively. In the intention-to-treat population (n = 171), the least square mean percentage change of serum estradiol was -89%, -85%, and -60% for exemestane once daily (n = 55), 3 times weekly (n = 56), and once weekly (n = 60), respectively. The difference in estradiol percentage change between the once-daily and 3-times-weekly arms was -3.6% (P for noninferiority = .37), whereas in compliant participants (n = 153), it was 2.0% (97.5% lower confidence limit, -5.6%; P for noninferiority = .02). Among secondary end points, Ki-67 and progesterone receptor were reduced in all arms, with median absolute percentage changes of -7.5%, -5.0%, and -4.0% for Ki-67 in the once-daily, 3-times-weekly, and once-weekly arms, respectively (once daily vs 3 times weekly, P = .31; once daily vs once weekly, P = .06), and -17.0%, -9.0%, and -7.0% for progesterone receptor, respectively. Sex hormone-binding globulin and high-density lipoprotein cholesterol had a better profile among participants in the 3-times-weekly arm compared with once-daily arm. Adverse events were similar in all arms. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, exemestane, 25 mg, given 3 times weekly in compliant patients was noninferior to the once-daily dosage in decreasing serum estradiol. This new schedule should be further studied in prevention studies and in women who do not tolerate the daily dose in the adjuvant setting. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02598557; EudraCT: 2015-005063-16.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Serrano D, Gandini S, Thomas P, et al. Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor-Positive Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2023. PMID: 36951827. doi:10.1001/jamaoncol.2023.0089

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。